Cargando…
What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?
In the past two decades, monoclonal antibodies (mAbs) have revolutionized the treatment of multiple sclerosis (MS). However, a remarkable number of mAbs failed due to negative study results were withdrawn because of unexpected serious adverse events (SAEs) or due to studies being halted for other re...
Autores principales: | Krämer, Julia, Wiendl, Heinz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294122/ https://www.ncbi.nlm.nih.gov/pubmed/35794296 http://dx.doi.org/10.1007/s13311-022-01246-3 |
Ejemplares similares
-
Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020) -
CRUSE – What the first 100 days have taught us
por: Neisinger, Sophia, et al.
Publicado: (2023) -
Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021) -
Monogenic Models: What Have the Single Gene Disorders Taught Us?
por: Klupa, Tomasz, et al.
Publicado: (2012) -
What helminth genomes have taught us about parasite evolution
por: ZAROWIECKI, MAGDALENA, et al.
Publicado: (2015)